{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:32Z","timestamp":1793191772320,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jtha.2025.03.034","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:26:32Z","timestamp":1744079192000},"page":"2164-2177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-6915","authenticated-orcid":false,"given":"Kenichi","family":"Ogiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Sasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.03.034_bib1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/hae.14803","article-title":"Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: a systematic literature review","volume":"29","author":"Mannucci","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.03.034_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2025.03.034_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.03.034_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102265","article-title":"Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada","volume":"7","author":"Fischer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.03.034_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.03.034_bib7","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.034_bib8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.034_bib9","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.034_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.034_bib11","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.03.034_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12670","article-title":"Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib14","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib15","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.034_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/hae.15015","article-title":"Bleeding control improves after switching to emicizumab: real-world experience of 177 children in the PedNet registry","volume":"30","author":"van der Zwet","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.03.034_bib17","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse\u2013Jarres","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.03.034_bib18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","article-title":"Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients","volume":"115","author":"Nakajima","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib21","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jtha.2024.03.022","article-title":"Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A","volume":"22","author":"Josset","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state","volume":"22","author":"Teranishi-Ikawa","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jim\u00e9nez\u2013Yuste","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2257.2004.00605.x","article-title":"Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference","volume":"26","author":"Okuda","year":"2004","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jtha.2025.03.034_bib27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","article-title":"A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X","volume":"112","author":"Ogiwara","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bjh.16574","article-title":"Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors","volume":"190","author":"Furukawa","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2491\/jjsth.31.93","article-title":"Appendix edition: hemostatic treatment guidelines for hemophilia patients the use of Hemlibra\u00ae (Emicizumab)","volume":"31","author":"Tokugawa","year":"2020","journal-title":"Jpn J Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib30","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1055\/s-0042-1756706","article-title":"Clot Waveform Analysis for Monitoring Hemostasis","volume":"49","author":"Nogami","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.14148","article-title":"The utility of thromboelastography in inherited and acquired bleeding disorders","volume":"174","author":"Nogami","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","article-title":"Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis","volume":"110","author":"Yada","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib34","article-title":"NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V","volume":"8","author":"Nakajima","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2024.03.021","article-title":"Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation","volume":"237","author":"Nakajima","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.034_bib36","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/hae.15106","article-title":"NXT007 does not interfere with the anticoagulant effects on tissue factor pathway inhibitor","volume":"30","author":"Nakajima","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.03.034_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bjh.15525","article-title":"Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V","volume":"183","author":"Yada","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.034_bib38","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1055\/s-0038-1636538","article-title":"Emicizumab, a bispecific antibody to factors IX\/IXa and X\/Xa, does not interfere with antithrombin or TFPI activity in vitro","volume":"2","author":"Noguchi-Sasaki","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2025.03.034_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056922","article-title":"Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial","volume":"12","author":"Ogiwara","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2025.03.034_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072565","article-title":"Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial","volume":"13","author":"Takeyama","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2025.03.034_bib41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.034_bib42","article-title":"Final Analysis results from the AGEHA study: emicizumab prophylaxis for acquired hemophilia A with or without immunosuppressive therapy","author":"Shima","year":"2024","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625002144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625002144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:11:44Z","timestamp":1782958304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625002144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1538783625002144"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.03.034","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}